170261 ⎘
Assays involving biological materials from specific organisms or of a specific nature from viruses; RNA viruses; Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus; Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV; HIV-1, HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, DC4-Binding site
HIV GP41 VARIANTS FOR IMMUNODIAGNOSTIC ASSAYS
#2ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#3NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#4NEUTRALIZING ANTIBODIES TO HIV-1 ENV AND THEIR USE
#5BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE
#6NEUTRALIZING ANTIBODIES TO GP120 AND THEIR USE
#7BROADLY NEUTRALIZING ANTI-HIV ANTIBODIES AND EPITOPE THEREFOR
#8HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO
#9RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION
#10Compositions and Methods for Determining Resistance to Inhibitors of Virus Enter Using Recombinant Virus Assays
#11Recombinant HIV-1 envelope proteins and their use
#12Neutralizing antibodies to GP120 and their use
#13ANTIBODY SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#14ANTIBODIES AND THE USES THEREOF
#15HIV BINDING AGENTS
#16EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
#1710E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use
#18Broadly Neutralizing Anti-HIV Antibodies and Epitope Therefor
#19ANTI-HIV ANTIBODIES
#20Neutralizing antibodies to HIV-1 Env and their use
#21Recombinant viral vectors
#22Methods of making anti-GP41 antibody-specific capture agents
#23RAPID QUANTITATIVE ASSAY TO ASSESS DURATION OF INFECTION
#24Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#25Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
#26Nucleic acids encoding broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 ENV subunits
#27Exosome-mediated diagnosis of human immunodeficiency virus infection
#28Recombinant HIV-1 envelope proteins and their use
#29High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
#30Exosome-mediated diagnosis of hepatitis virus infections and diseases
#31Method for detecting HIV-1-specific antibodies using clade C env polypeptides
#32Recombinant viral vectors
#33HUMORAL IMMUNITY SIGNATURES FOR ANTIBODY-MEDIATED IMMUNE RESPONSES AND TREATMENTS
#34Neutralizing antibodies to gp120 and their use
#35SMALL MOLECULE INHIBITORS OF GP120-MEDIATED HIV INFECTION AND METHODS OF USE
#36Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits
#37Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#38Recombinant viral vectors
#39EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES
#40Recombinant HIV-1 envelope proteins and their use
#41Exosome-mediated diagnosis of hepatitis virus infections and diseases
#42Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
#43Methods for determining susceptibility to coreceptor inhibitors
#44Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
#45Exosome-mediated diagnosis of hepatitis virus infections and diseases
#46Method for the vaccination against HIV
#47Methods and compositions related to inhibition of viral entry
#48Drug target site within GP120 of HIV
#49High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
#50Fusion protein for HIV-1 gp120 antigen detection
#51Recombinant viral vectors
#52Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies
#53Methods for identifying HIV neutralizing antibodies
#54Method for diagnosing and differentiating HIV-2 infections
#55TESTING DEVICE
#56Anti-GP41 antibody-specific capture agents, compositions, and methods of using and making
#57METHODS OF IDENTIFYING NOVEL HIV-1 IMMUNOGENS
#58COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#59Alpha1 proteinase inhibitor peptides methods and use
#60METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A VIRUS TO AN ATTACHMENT INHIBITOR
#61Exosome-mediated diagnosis of hepatitis virus infections and diseases
#62Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
#63Drug target site within gp120 of HIV
#64Rapid selection method for HIV gp-120 variants
#65Active cores of peptide triazole HIV-1 entry inhibitors
#66Method for the detection of HIV-1 antibodies utilizing a peptide containing a novel gp41 epitope
#67Peptides mimicking HIV-1 viral epitopes in the V2 loop for the GP120 surface envelope glycoprotein
#68Molecular determinants in the HIV-1 envelope associated with enhanced ability to enter CXCR4-expressing cells
#69ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE
#70Detection of HIV-related proteins in urine
#71Detection of HIV-related proteins in urine
#72ALPHABODIES FOR HIV ENTRY INHIBITION
#73Active cores of peptide triazole HIV-1 entry inhibitors
#74Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
#75METHODS FOR MAKING HIV VACCINES AND RELATED COMPOSITIONS
#76Methods for the detection of HIV-1-specific antibodies employing GP41 polypeptides
#77COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS
#78COMPOSITIONS AND METHODS FOR THE DETECTION OF HIV-1/HIV-2 INFECTION
#79Peptides and methods of use as therapeutics and screening agents
#80Antigen constructs useful in the detection and differentiation of antibodies to HIV
#81HIGH THROUGHPUT PROTEIN INTERACTION ASSAY
#82MOLECULARLY IMPRINTED POLYMERS FOR DETECTING HIV-1
#83RECOMBINANT VIRAL VECTORS
#84NATIVE GP41 ASSAY
#85Methods and compositions related to inhibition of viral entry
#86Compositions and methods for determining whether a subject would benefit from co-receptor inhibitor therapy
#87Detection of HIV-related proteins in urine
#88Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
#89Method for determining human immunodeficiency virus (HIV) coreceptor utilization by examining gp41 molecular determinants
#90Antigen constructs useful in the detection and differentiation of antibodies to HIV
#91Alpha1 proteinase inhibitor peptides methods and use
#92Methods for the detection of HIV-1 antibodies employing polypeptides obtained from gag P6 protein
#93Env polypeptide complexes and methods of use
#94Method for preventing HIV-1 infection of CD4 cells
#95Methods for Treating Hiv by Inhibiting Cd4 Down-Modulation
#96CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
#97Detecting early HIV infection in genital tract cells and secretions
#98Antigen constructs useful in the detection and differentiation of antibodies to HIV
#99Antigen constructs useful in the detection and differentiation of antibodies to HIV
#100Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein
#101HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR ASSAY
#102Peptides for the detection of HIV-1 group O
#103Antigen constructs useful in the detection and differentiation of antibodies to HIV
#104Methods and compositions, relating to hiv gp41 antigens and other hiv envelope antigens
#105Method for preventing HIV-1 infection of CD4+ cells
#106Compositions and methods for determining resistance to inhibitors of virus entry using recombinant virus assays
#107Compositions and methods for diagnosing, preventing, and treating cancers
#108Inhibitors of HIV membrane fusion
#109Anti-fusion assay
#110HIV-specific T-cell induction